Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
3.580
+0.060 (1.70%)
Mar 31, 2025, 1:13 PM EDT - Market open
Foghorn Therapeutics Revenue
In the year 2024, Foghorn Therapeutics had annual revenue of $22.60M, down -33.83%. Foghorn Therapeutics had revenue of $2.86M in the quarter ending December 31, 2024, a decrease of -50.49%.
Revenue (ttm)
$22.60M
Revenue Growth
-33.83%
P/S Ratio
8.55
Revenue / Employee
$201,804
Employees
112
Market Cap
199.09M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
FHTX News
- 5 days ago - Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting - GlobeNewsWire
- 24 days ago - Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewsWire
- 4 weeks ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewsWire
- 6 months ago - Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - GlobeNewsWire
- 6 months ago - Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewsWire